Literature DB >> 29231194

Breast cancer in 2017: Spurring science, marking progress, and influencing history.

Jose Perez-Garcia1, Javier Cortes2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29231194     DOI: 10.1038/nrclinonc.2017.191

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  12 in total

1.  Adjuvant Capecitabine for Breast Cancer.

Authors:  Masakazu Toi; Norikazu Masuda; Yasuo Ohashi
Journal:  N Engl J Med       Date:  2017-08-24       Impact factor: 91.245

2.  MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.

Authors:  George W Sledge; Masakazu Toi; Patrick Neven; Joohyuk Sohn; Kenichi Inoue; Xavier Pivot; Olga Burdaeva; Meena Okera; Norikazu Masuda; Peter A Kaufman; Han Koh; Eva-Maria Grischke; Martin Frenzel; Yong Lin; Susana Barriga; Ian C Smith; Nawel Bourayou; Antonio Llombart-Cussac
Journal:  J Clin Oncol       Date:  2017-06-03       Impact factor: 44.544

3.  Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

Authors:  Gunter von Minckwitz; Marion Procter; Evandro de Azambuja; Dimitrios Zardavas; Mark Benyunes; Giuseppe Viale; Thomas Suter; Amal Arahmani; Nathalie Rouchet; Emma Clark; Adam Knott; Istvan Lang; Christelle Levy; Denise A Yardley; Jose Bines; Richard D Gelber; Martine Piccart; Jose Baselga
Journal:  N Engl J Med       Date:  2017-06-05       Impact factor: 91.245

4.  Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.

Authors:  Hope S Rugo; Abhijit Barve; Cornelius F Waller; Miguel Hernandez-Bronchud; Jay Herson; Jinyu Yuan; Rajiv Sharma; Mark Baczkowski; Mudgal Kothekar; Subramanian Loganathan; Alexey Manikhas; Igor Bondarenko; Guzel Mukhametshina; Gia Nemsadze; Joseph D Parra; Maria Luisa T Abesamis-Tiambeng; Kakhaber Baramidze; Charuwan Akewanlop; Ihor Vynnychenko; Virote Sriuranpong; Gopichand Mamillapalli; Sirshendu Ray; Eduardo P Yanez Ruiz; Eduardo Pennella
Journal:  JAMA       Date:  2017-01-03       Impact factor: 56.272

5.  Potential regional differences for the tolerability profiles of fluoropyrimidines.

Authors:  Daniel G Haller; Jim Cassidy; Stephen J Clarke; David Cunningham; Eric Van Cutsem; Paulo M Hoff; Mace L Rothenberg; Leonard B Saltz; Hans-Joachim Schmoll; Carmen Allegra; Joseph R Bertino; Jean-Yves Douillard; Bengt G Gustavsson; Gerard Milano; Michael O'Connell; Youcef Rustum; Josep Tabernero; Frank Gilberg; Florin Sirzén; Chris Twelves
Journal:  J Clin Oncol       Date:  2008-05-01       Impact factor: 44.544

6.  Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

Authors:  Massimo Cristofanilli; Nicholas C Turner; Igor Bondarenko; Jungsil Ro; Seock-Ah Im; Norikazu Masuda; Marco Colleoni; Angela DeMichele; Sherene Loi; Sunil Verma; Hiroji Iwata; Nadia Harbeck; Ke Zhang; Kathy Puyana Theall; Yuqiu Jiang; Cynthia Huang Bartlett; Maria Koehler; Dennis Slamon
Journal:  Lancet Oncol       Date:  2016-03-03       Impact factor: 41.316

7.  Palbociclib and Letrozole in Advanced Breast Cancer.

Authors:  Richard S Finn; Miguel Martin; Hope S Rugo; Stephen Jones; Seock-Ah Im; Karen Gelmon; Nadia Harbeck; Oleg N Lipatov; Janice M Walshe; Stacy Moulder; Eric Gauthier; Dongrui R Lu; Sophia Randolph; Véronique Diéras; Dennis J Slamon
Journal:  N Engl J Med       Date:  2016-11-17       Impact factor: 91.245

8.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

Authors:  Mark Robson; Seock-Ah Im; Elżbieta Senkus; Binghe Xu; Susan M Domchek; Norikazu Masuda; Suzette Delaloge; Wei Li; Nadine Tung; Anne Armstrong; Wenting Wu; Carsten Goessl; Sarah Runswick; Pierfranco Conte
Journal:  N Engl J Med       Date:  2017-06-04       Impact factor: 91.245

9.  MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.

Authors:  Matthew P Goetz; Masakazu Toi; Mario Campone; Joohyuk Sohn; Shani Paluch-Shimon; Jens Huober; In Hae Park; Olivier Trédan; Shin-Cheh Chen; Luis Manso; Orit C Freedman; Georgina Garnica Jaliffe; Tammy Forrester; Martin Frenzel; Susana Barriga; Ian C Smith; Nawel Bourayou; Angelo Di Leo
Journal:  J Clin Oncol       Date:  2017-10-02       Impact factor: 44.544

10.  Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

Authors:  Gabriel N Hortobagyi; Salomon M Stemmer; Howard A Burris; Yoon-Sim Yap; Gabe S Sonke; Shani Paluch-Shimon; Mario Campone; Kimberly L Blackwell; Fabrice André; Eric P Winer; Wolfgang Janni; Sunil Verma; Pierfranco Conte; Carlos L Arteaga; David A Cameron; Katarina Petrakova; Lowell L Hart; Cristian Villanueva; Arlene Chan; Erik Jakobsen; Arnd Nusch; Olga Burdaeva; Eva-Maria Grischke; Emilio Alba; Erik Wist; Norbert Marschner; Anne M Favret; Denise Yardley; Thomas Bachelot; Ling-Ming Tseng; Sibel Blau; Fengjuan Xuan; Farida Souami; Michelle Miller; Caroline Germa; Samit Hirawat; Joyce O'Shaughnessy
Journal:  N Engl J Med       Date:  2016-10-07       Impact factor: 91.245

View more
  1 in total

1.  Localization of GPSM2 in the Nucleus of Invasive Breast Cancer Cells Indicates a Poor Prognosis.

Authors:  Mingming Deng; Zhe Zhang; Bofang Liu; Kezuo Hou; Xiaofang Che; Xiujuan Qu; Yunpeng Liu; Xuejun Hu; Ye Zhang; Qingjie Lv
Journal:  Front Oncol       Date:  2020-03-03       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.